Physician profile
Alison Macleod
NPI 1932151818
$3,248.41
in general payments reported to CMS, 2019-2025
31 companies · $784 in 2025
The $784 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,728 · 2022: $173 · 2023: $24.63 · 2024: $539 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $849.33 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $511.09 | 2021-2022 | |
| Lilly USA, LLC | $234.34 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $226.37 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $186.10 | 2021 | |
| Pfizer INC. | $150.75 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $139.15 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $127.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.59 | 2021-2022 | |
| Stryker Corporation | $74.77 | 2025 | Flowtriever, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Supernus Pharmaceuticals, INC. | $74.32 | 2021-2022 | |
| Eisai INC. | $67.57 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $49.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $49.28 | 2021-2024 | Spravato |
| Astellas Pharma US INC | $42.84 | 2024 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $40.34 | 2025 | Sapien 3 Ultra Resilia |
| Jazz Pharmaceuticals INC. | $31.87 | 2021 | |
| Merck Sharp & Dohme LLC | $31.11 | 2021 | |
| Biogen, INC. | $29.49 | 2024 | Skyclarys |
| Daiichi Sankyo INC. | $28.68 | 2025 | Injectafer |
| Viiv Healthcare Company | $26.90 | 2024 | Apretude |
| Amgen INC. | $25.41 | 2021 | |
| Shield Therapeutics INC | $23.52 | 2024 | |
| Acadia Pharmaceuticals INC | $22.86 | 2021 | |
| Exact Sciences Corporation | $22.57 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $20.94 | 2021 | |
| Glaxosmithkline, LLC. | $20.73 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.72 | 2024 | Quviviq |
| Currax Pharmaceuticals LLC | $14.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.84 | 2021 | |
| Genentech USA, INC. | $4.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Macleod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.